NCT02372903View on ClinicalTrials.gov

Efficacy of Palmitoylethanolamide-polydatin Combination on Chronic Pelvic Pain in Patients With Endometriosis

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions
EndometriosisChronic Pelvic Pain
Interventions
DRUG

Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin

Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days

Trial Locations (1)

09042

University of Cagliari,Obstetrics and Gynecological Department,, Monserrato

All Listed Sponsors
lead

University of Cagliari

OTHER

NCT02372903 - Efficacy of Palmitoylethanolamide-polydatin Combination on Chronic Pelvic Pain in Patients With Endometriosis | Biotech Hunter | Biotech Hunter